Trials / Completed
CompletedNCT04858204
Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer
Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer: a French Observational Multicenter Study of 259 Patients (ABCT-IMMUNOBZH)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 259 (actual)
- Sponsor
- University Hospital, Brest · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Data regarding nivolumab as second line treatment in advanced non-small cell lung cancer (NSCLC) are based on selected populations and might not reflect daily practice. Investigators aimed at assessing efficacy and safety of nivolumab in a real-life setting and determining a subtype of NSCLC patients that are more likely to benefit from immunotherapy.
Conditions
Timeline
- Start date
- 2017-04-14
- Primary completion
- 2017-10-31
- Completion
- 2017-11-01
- First posted
- 2021-04-26
- Last updated
- 2021-04-26
Locations
7 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04858204. Inclusion in this directory is not an endorsement.